Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Ribosome biogenesis and protein synthesis are fundamental rate-limiting steps for cell
growth and proliferation. The ribosomal proteins (RPs), comprising the structural parts of the …
growth and proliferation. The ribosomal proteins (RPs), comprising the structural parts of the …
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
G Garcia‐Manero - American journal of hematology, 2023 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
AS Sperling, CJ Gibson, BL Ebert - Nature Reviews Cancer, 2017 - nature.com
Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of
mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal …
mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal …
Lenalidomide induces ubiquitination and degradation of CK1α in del (5q) MDS
Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with
deletion of chromosome 5q (del (5q)). Here, we demonstrate that lenalidomide induces the …
deletion of chromosome 5q (del (5q)). Here, we demonstrate that lenalidomide induces the …
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
AM Zeidan, U Platzbecker… - Blood, The Journal …, 2023 - ashpublications.org
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …
clinical presentations and outcomes. The initial response criteria developed by the …
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
T De Witte, D Bowen, M Robin… - Blood, The Journal …, 2017 - ashpublications.org
An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …
Treatment of MDS
U Platzbecker - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …
Diagnosis and treatment of myelodysplastic syndromes: a review
MA Sekeres, J Taylor - Jama, 2022 - jamanetwork.com
Importance Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic
syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow …
syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow …
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg… - Blood, The Journal …, 2013 - ashpublications.org
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …
an Expert Panel was selected according to the framework elements of the National Institutes …
Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
PL Greenberg, RM Stone, A Al-Kali, SK Barta… - Journal of the National …, 2017 - jnccn.org
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …